A supercritical CO2 extract of a CBD-rich cannabis genotype significantly reduced pro-inflammatory cytokines in cell studies and showed dose-dependent anti-inflammatory and analgesic effects in animal models.
Researchers studying cannabis pharmacology, people interested in full-spectrum vs. isolated CBD, and clinicians following preclinical cannabis pain research.
CBD-rich extract reduced TNF-alpha and IL-6 without cytotoxicity
What the researchers found
The CBD-rich cannabis extract (CSFE) significantly reduced TNF-alpha and IL-6 production in LPS-stimulated macrophages at 3, 10, and 30 mcg/ml without cytotoxicity. In animal models, it demonstrated dose-dependent decreases in inflammation and improvements in pain relief.
Why it matters
Most cannabis pain research focuses on isolated CBD or THC. This study examines a full-spectrum CBD-rich extract with characterized chemical composition, supporting the idea that the entourage effect of multiple cannabis compounds may contribute to therapeutic outcomes.
The numbers in context
62 compounds identified in the extract. Major cannabinoids: CBD (9.75%), CBDA (2.76%), THC (4.40%). Pro-inflammatory cytokine reduction at 3, 10, and 30 mcg/ml concentrations. Significant dose-dependent anti-inflammatory and analgesic effects in animal models.
How the study worked
Chemical characterization of a supercritical CO2 extract of Cannabis sativa genotype CIM-CS-64 using GC-FID, GC-MS, HPLC, HRMS, and NMR. In vitro anti-inflammatory testing in LPS-stimulated macrophages. In vivo inflammation and pain models in small laboratory animals.
What this study cannot tell us
Animal study results may not translate to humans. The extract contains THC (4.40%) alongside CBD, so effects cannot be attributed to CBD alone. Specific animal models and doses used in vivo were not detailed in the abstract.
How to read the evidence
Preliminary: preclinical study with in vitro and animal data only, no human testing.
When this study was published
Published 2026.
The bigger picture
This study connects rigorous chemical analysis of a specific cannabis genotype with functional testing, providing a model for how future cannabis-based medicine development might proceed with standardized, well-characterized extracts.
Questions still open
- How does this full-spectrum extract compare to isolated CBD for pain and inflammation? Would the 4.40% THC content produce psychoactive effects at therapeutic doses in humans? Can these results be replicated with other CBD-dominant cannabis genotypes?
Common questions
Can CBD-rich cannabis extract reduce inflammation?
What was in the cannabis extract studied?
Read the original research
Therapeutic potential of cannabidiol-rich Cannabis sativa to mitigate the severity of inflammation and pain: A pre-clinical study.
Journal of ethnopharmacology, 357, 120856
Citation
Singh, Munmun Kumar; Sen, Sumati; Singh, Swati; Aftab, Nashra; Kumar, Birendra; Gupta, Namita; Tandon, Sudeep; Bawankule, Dnyaneshwar Umrao; Verma, Ram Swaroop. (2026). Therapeutic potential of cannabidiol-rich Cannabis sativa to mitigate the severity of inflammation and pain: A pre-clinical study.. Journal of ethnopharmacology, 357, 120856. https://doi.org/10.1016/j.jep.2025.120856
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk